(S,R,S)-AHPC-PEG3-propionic acid is a highly specialized E3 Ligase Ligand-Linker Conjugate designed for use in PROTAC (Proteolysis Targeting Chimera) research and drug discovery. This compound features the well-characterized (S,R,S)-AHPC moiety, which selectively binds to the Von Hippel-Lindau (VHL) E3 ubiquitin ligase, linked via a polyethylene glycol (PEG3) spacer to a propionic acid functional group. The PEG3 linker provides optimal flexibility and solubility for constructing bifunctional molecules. As a key intermediate in the synthesis of PROTAC molecules, (S,R,S)-AHPC-PEG3-propionic acid enables the targeted degradation of disease-related proteins by recruiting the VHL E3 ligase to a specific target protein. This results in the ubiquitination and subsequent proteasomal degradation of the target, offering a powerful approach for therapeutic intervention, particularly in cancer and neurodegenerative disease research. With its robust design, this conjugate streamlines the development of next-generation PROTACs and other protein degraders, supporting both academic and pharmaceutical research into selective protein knockdown strategies.
Structure of 2140807-42-5
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
(S,R,S)-AHPC-PEG3-propionic acid is a specialized E3 ligase ligand-linker conjugate designed for use in targeted protein degradation approaches, particularly in the design and synthesis of PROTACs (Proteolysis Targeting Chimeras). The AHPC moiety is a thalidomide derivative recognized for efficiently recruiting the von Hippel-Lindau (VHL) E3 ubiquitin ligase, while the PEG3-propionic acid linker enhances solubility and flexibility for conjugation with diverse target-binding ligands.
Mechanism
This molecule functions as a critical component in PROTAC strategy by utilizing the AHPC moiety to bind VHL E3 ligase. The PEG3-propionic acid linker provides structural flexibility and optimal spatial arrangement, improving the formation and stability of the ternary complex between the E3 ligase and the target protein. Through conjugation of (S,R,S)-AHPC-PEG3-propionic acid to a ligand specific for a protein of interest, the resulting PROTAC molecule brings the target protein into close proximity with the E3 ligase. This proximity induces ubiquitination of the target protein, leading to its recognition and degradation by the cellular proteasome system.
Applications
(S,R,S)-AHPC-PEG3-propionic acid is widely utilized in medicinal chemistry and chemical biology for the rational design of VHL-recruiting PROTACs. Applications include the synthesis of bifunctional molecules for targeted degradation of challenging proteins, proof-of-concept studies in drug discovery, and validation of novel drug targets. Its superior solubility and functional handle enable flexible conjugation, making it ideal for research in oncology, immunology, neurodegeneration, and other therapeutic areas where selective protein degradation is desired.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.